Is primary breast melanoma a true pathological entity? The argument against it.

Breast melanoma Metastatic melanoma Primary melanoma of the breast parenchyma

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
30 Sep 2024
Historique:
received: 25 09 2023
revised: 28 08 2024
accepted: 29 08 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 23 9 2024
Statut: epublish

Résumé

Previous studies have reported cases of primary melanoma of the breast parenchyma (PMBP), but the pathogenesis of this disease remains poorly understood. We review the presentation and outcomes of reported cases and provide detailed pathological analysis of four additional cases. Furthermore, we discuss potential theories regarding the pathogenesis of this clinical presentation. We identified 29 published studies (n = 95 patients) and report four new cases (n = 99). Ninety-one (92 %) patients were female, with a median age of 50 years. Previous skin melanomas were reported by 56 % of patients, with the trunk being the most common location (32.7 %) followed by the upper extremities (20 %). The most common tumor location reported (n = 73) was the right (49 %) upper outer quadrant (56 %). The median time from skin melanoma diagnosis to the presence of a breast mass was 65 months (1-192). Nodal status at presentation was reported in n = 67 (68 %) patients. Of these, positive nodal metastases were seen in 40.3 %, while distant metastatic disease at presentation was reported in 30 % of patients. Surgery was performed in 66 %, being partial mastectomy (PM) the most common procedure in 82 %. Adjuvant therapy was described in 38 patients. The reported (n = 12) median survival was 11.5 (1-70) months. Melanomas identified in the breast parenchyma are likely the result of nodal or hematogenous spread from previously known or unknown melanomas, and should not be considered as PMBP. Management should be multidisciplinary, including surgical excision aimed at obtaining negative margins with lymphadenectomy of clinically positive nodes and neoadjuvant/adjuvant immunotherapy.

Sections du résumé

Background UNASSIGNED
Previous studies have reported cases of primary melanoma of the breast parenchyma (PMBP), but the pathogenesis of this disease remains poorly understood. We review the presentation and outcomes of reported cases and provide detailed pathological analysis of four additional cases. Furthermore, we discuss potential theories regarding the pathogenesis of this clinical presentation.
Results UNASSIGNED
We identified 29 published studies (n = 95 patients) and report four new cases (n = 99). Ninety-one (92 %) patients were female, with a median age of 50 years. Previous skin melanomas were reported by 56 % of patients, with the trunk being the most common location (32.7 %) followed by the upper extremities (20 %). The most common tumor location reported (n = 73) was the right (49 %) upper outer quadrant (56 %). The median time from skin melanoma diagnosis to the presence of a breast mass was 65 months (1-192). Nodal status at presentation was reported in n = 67 (68 %) patients. Of these, positive nodal metastases were seen in 40.3 %, while distant metastatic disease at presentation was reported in 30 % of patients. Surgery was performed in 66 %, being partial mastectomy (PM) the most common procedure in 82 %. Adjuvant therapy was described in 38 patients. The reported (n = 12) median survival was 11.5 (1-70) months.
Conclusion UNASSIGNED
Melanomas identified in the breast parenchyma are likely the result of nodal or hematogenous spread from previously known or unknown melanomas, and should not be considered as PMBP. Management should be multidisciplinary, including surgical excision aimed at obtaining negative margins with lymphadenectomy of clinically positive nodes and neoadjuvant/adjuvant immunotherapy.

Identifiants

pubmed: 39309840
doi: 10.1016/j.heliyon.2024.e37224
pii: S2405-8440(24)13255-0
pmc: PMC11414497
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e37224

Informations de copyright

© 2024 The Authors. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alexis R Narvaez-Rojas (AR)

Department of Radiation Oncology, Maimonides Cancer Center, Brooklyn, NY, USA.
International Coalition on Surgical Research, Universidad Nacional Autónoma de Nicaragua, UNAN, Managua, Nicaragua.

Samantha Linhares (S)

University of Miami Miller School of Medicine, Miami, FL, USA.

Shaina Sedighim (S)

Department of Surgery, University of California, Irvine, Orange, CA, USA.

Kyle Daniel Klingbeil (KD)

Department of Surgery, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.

Clara Milikowski (C)

University of Miami Miller School of Medicine, Miami, FL, USA.
Departments of Pathology, Division of Hematology Oncology at University of Miami Miller School of Medicine, Miami, FL, USA.

George Elgart (G)

University of Miami Miller School of Medicine, Miami, FL, USA.
Departments of Dermatology, Division of Hematology Oncology at University of Miami Miller School of Medicine, Miami, FL, USA.

Natalia Jaimes (N)

University of Miami Miller School of Medicine, Miami, FL, USA.
Departments of Dermatology, Division of Hematology Oncology at University of Miami Miller School of Medicine, Miami, FL, USA.

Lynn Feun (L)

University of Miami Miller School of Medicine, Miami, FL, USA.
Departments of Medicine, Division of Hematology Oncology at University of Miami Miller School of Medicine, Miami, FL, USA.

Jose Lutzky (J)

University of Miami Miller School of Medicine, Miami, FL, USA.
Departments of Medicine, Division of Hematology Oncology at University of Miami Miller School of Medicine, Miami, FL, USA.

Gabriel De la Cruz Ku (G)

Universidad Cientifica Del Sur, Lima, Peru.

Eli Avisar (E)

University of Miami Miller School of Medicine, Miami, FL, USA.
Department of Surgery, Division of Surgical Oncology at University of Miami Miller School of Medicine, Miami, FL, USA.

Mecker G Möller (MG)

University of Miami Miller School of Medicine, Miami, FL, USA.
Department of Surgery, Division of Surgical Oncology at University of Miami Miller School of Medicine, Miami, FL, USA.

Classifications MeSH